



National Cancer Policy Forum Biological Effectors of SDOH in Cancer: Identification and Mitigation Policy Opportunities to Address SDOH on Cancer Outcomes and Improve the Evidence Base on the Impact of SDOH on Biological Outcomes

The Research Perspective

March 21, 2024

Oluwadamilola "Lola" Fayanju, MD, MA, MPHS, FACS The Helen O. Dickens Presidential Associate Professor Chief, Division of Breast Surgery The University of Pennsylvania

Funding

- NIH Award Number 1K08CA241390 (PI: Fayanju, 2019-present)
- NIH Award Number P50CA244690 (PI: Bekelman, 2022-present)
- Philanthropic Funds from The Haas Family (2021-present)
- Gilead Sciences, Inc (PI: Fayanju, 2023-present)
- Breast Cancer Research Foundation (BCRF) (PI: Fayanju, 2023-present)



Collecting and Intervening upon Modifiable Contributors to Disparity: Social Determinants of Health


- ↑↑↑ Rates of missingness and misinformation of social history data in EMR
- Who collects this data?
 - Temporal and financial pressures in outpatient primary and specialty care
 - Patient vs clinic staff vs provider entry
 - Data entry platform: paper/pencil, electronic, hybrid
- When do we collect this data?
 - Periodic
 - Event-, procedure-, or screen-triggered
 - At home or in the healthcare setting
- Who does this data belong to, and what do we do with it?





The NCCN Distress Thermometer

- ► Duke Cancer Center, Jan 2014 Jul 2016
- ► 1029 women → 12,569 visits (67 mos f/u)
- ► Increased distress over time for women breast cancer who were...
 - Unmarried
 - Medicaid recipients
- Median DT score = 4 (scale 0-10) but....
- Black patients
 - Reported lower baseline scores
 - Experienced less improvement in distress over time




version 2.2016. O'1/2016 it file PoCMC contact Practices outlinearies (and uniforms in such contents of websites) and a basement of versions of real authors regarded greater was contently accepted propositions to treatment. Any collections seeking to apply on consult the NCCN acceptance in practice of the such contents of websites of management of the contents of websites and contents of websites and contents of websites are represented by the content of management of the content of the c






Levels and causes of distress at 1st visit – Breast Cancer

- ► Asian/PI & Hispanic patients had highest median DT scores (score = 5, p=0.01)
- ► Black patients had lowest median DT score (3, IQR 0-6)
- ► Emotional, physical, and practical stressors → ↑ distress
- ► Black patients ↑ likely to report <u>no</u> distress than Whites
 - ZINB zero model OR 2.72, 95% CI 1.68-4.40
- ► Black patients only racial/ethnic group with median DT score IQR 0-6) below the automatic referral threshold score of 4
- ► No difference in number of stressors (p=0.07)



Impact of distress on time-to-evaluation & time-to-treatment





Impact of distress on time-to-evaluation & time-to-treatment



Black race


Practical stressors



Conclusion

By the time someone arrives for her visit, the die has been cast. We have to start sooner.

Fayanju OM, et al. Cancer. 2021 Mar 1;127(5):757-768





Oncologists are information gatekeepers at key inflection points during patients' lives.





Collecting and Intervening upon Modifiable Contributors to Disparity: Social Determinants of Health

- ↑↑↑ Rates of missingness and misinformation of social history data in EMR
- Who collects this data?
 - Temporal and financial pressures in outpatient primary and specialty care
 - Patient vs clinic staff vs provider entry
 - Data entry platform: paper/pencil, electronic, hybrid
- When do we collect this data?
 - Periodic
 - Event-, procedure-, or screen-triggered
 - At home or in the healthcare setting
- Who does this data belong to, and what do we do with it?





Collecting and Intervening upon Modifiable Contributors to Disparity: Social Determinants of Health

- ↑↑↑ Rates of missingness and misinformation of social history data in EMR
- Who collects this data?
 - Temporal and financial pressures in outpatient primary and specialty care
 - Patient vs clinic staff vs provider entry
 - Data entry platform: paper/pencil, electronic, hybrid
- When do we collect this data?
 - Periodic
 - Event-, procedure-, or screen-triggered
 - At home or in the healthcare setting
- Who does this data belong to, and what do we do with it?





Department of Surgery I Division of Breast Surgery



Effect of Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and Enhanced Navigation on Care Delivery for Patients with Breast Cancer NCT06019988

Principal Investigator: Oluwadamilola "Lola" Fayanju, MD, MA, MPHS, FACS

Sponsor: Gilead Sciences, Inc.



Overall Goals



- ► We propose that early, anticipatory point-of-service screening for SBDOH operationalized through electronic health records and linked with interventions could redress modifiable contributors to breast cancer disparities.
- ► Our goal is to improve the equity, effectiveness, and efficiency of care for patients with breast cancer across the continuum from screening to treatment to survivorship.


Study Objectives

- Aim to identify the optimal combinations of modality and data collection instrument to facilitate SBDOH collection among diverse patients with breast cancer at Abramson Cancer Center (ACC)
 - To compare rates of SBDOH data collection using 3 different self-administered instruments designed for SBDOH data capture vs. usual care (i.e., unstructured data collection)
 - To compare rates of SBDOH data collection by modality (Epic patient portal/MyPennMedicine [MPM], chatbot, telephone interactive voice response) and assess time to evaluation (i.e., time from biopsy to first consultation with an oncologist)
 - To evaluate (via qualitative interviews) contextual mechanisms contributing to the effectiveness of data collection tools and modalities described in the trial

Enrollment

► Patients will be eligible based on a new patient visit (NPV) for breast cancer at HUP, PPMC, PAH, or Radnor from Mar 2024 to Feb 2025 (Goal N=2500)

► All patients who are diagnosed via percutaneous needle biopsy at Penn Radiology (internal) and all patients with a new (external) diagnosis of non-metastatic cancer who schedule an NPV with breast surgery will be contacted



Timeline to Trial Initiation

- December 2021: Preliminary conversations with industry sponsor
- ► May 2022-Feb 2023: Budget finalization and contract negotiation with industry sponsor
- March 14, 2023: Discovery Workshop at the Inn at Penn, Philadelphia, PA
- March-August 2023: Protocol development in response to Discovery Workshop feedback
- ▶ July 2023: Began working with Way to Health (W2H) to adapt surveys into chatbot and IVR formats
- August 18, 2023: IRB Protocol approved
- ► August-October 2023:
 - Testing and troubleshooting W2H platforms by study team & pt advocates
 - Building Epic infrastructure to ensure workflow could accommodate:
 - Randomization to instrument
 - Assigning patients to survey and sending surveys to patient in user-friendly manner
 - Presentation of response data to clinicians
 - Patient opt-outs
 - Closing surveys after 48 hrs and transferring non-responders to W2H; reopening charts of W2H non-responders to administer at NPV
- October 2023-February 2024: Integrating Epic and W2H
- March 12, 2024: Trial Launch!





Obstacles to Trial Initiation



- Technical
 - Limitation of existing systems (Way to Health and Epic)
 - Integration of existing systems
- People/Stakeholders
 - Unexpected concerns from key stakeholders (radiology, SW)
- Institutional
 - Unanticipated review and approval by institutional entities (e.g., Epic Questionnaire Committee, Epic Governance Board)





